Literature DB >> 8157550

The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.

C Catchpole1, J M Andrews, J Woodcock, R Wise.   

Abstract

The pharmacokinetics of ciprofloxacin following single doses of 400 mg i.v. and 750 mg po were compared in six healthy volunteers. Concentrations of ciprofloxacin were measured in plasma, cantharides induced blister fluid and urine, by microbiological assay and high performance liquid chromatography (HPLC). Mean peak plasma concentration was 6.7 +/- 1.4 mg/L after i.v. and 3.9 +/- 1.7 mg/L after oral administration with mean elimination half-lives of 4.2 and 4.0 h respectively. Mean area under the concentration versus time curve (AUC) was greater following oral administration (19.2 +/- 1.1 mg/L.h versus 14.2 +/- 1.1 mg/L.h). Blister fluid peak concentrations following i.v. and oral administration were 2.6 +/- 1.3 mg/L and 2.28 +/- 1.2 mg/L respectively. The elimination half-life from blister fluid was 4.1 +/- 1.1 h and the AUC 13.8 +/- 1.1 mg/L.h following i.v. administration compared with 4.6 +/- 1.5 h and 20.3 +/- 1.3 mg/L.h for the oral dose. A mean of 50.8% of i.v. administered drug and 39.6% or orally administered drug was excreted in urine in 24 h as measured by HPLC. The corresponding values by microbiological assay were greater, suggesting excretion of active metabolites. Both i.v. and oral doses produced levels in blister fluid concentration above the MICs for most Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae and Neisseria spp. at 12 h post dose. The pharmacokinetic data from inflammatory fluid indicate that ciprofloxacin 400 mg i.v. is more equivalent to 750 mg po than the plasma pharmacokinetic data suggest.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157550     DOI: 10.1093/jac/33.1.103

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Effects of new quinolones on transepithelial electrical potential difference of tracheal mucosa in vivo.

Authors:  S Kanoh; J Tamaoki; M Kondo; Y Nagano; A Nagai
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration.

Authors:  R Wise; J M Andrews; G Marshall; G Hartman
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.

Authors:  Andrej Trampuz; Gerd Laifer; Markus Wenk; Zarko Rajacic; Werner Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

Authors:  R Wise; D Mortiboy; J Child; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  The population dynamics of antimicrobial chemotherapy.

Authors:  M Lipsitch; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice daily.

Authors:  B Nia; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

8.  Tinnitus and ciprofloxacin.

Authors:  J Paul; N M Brown
Journal:  BMJ       Date:  1995-07-22

9.  New and future antibiotics in the treatment of acute respiratory tract infections.

Authors:  R Wise
Journal:  Thorax       Date:  1995-03       Impact factor: 9.139

10.  Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.